In 2021, our team worked together to deliver strong results across our core business with impressive EYLEA and Dupixent growth, while also helping address the ongoing pandemic by delivering REGEN-COV to millions of patients. For 2022, we remain focused on building on EYLEA's success, expanding approvals and patient reach for Dupixent, pursuing new indications for Libtayo, and reading out data from our oncology pipeline – all while continuing to progress our diversified earlier-stage pipeline. We also remain committed to our efforts to fight the COVID-19 pandemic and address the significant need for effective treatments and preventative approaches to SARS-CoV-2. With growth continuing across our existing portfolio and investments in our Research & Development engine supported by our strong balance sheet, we are well positioned for sustainable long-term growth.
Key 2021 business updates
& Development efforts
(19% increase over 2020)2
(53% increase over 2020)3
(32% increase over 2020)4
Civic 50: Most Community-Minded Companies in the Nation
Dow Jones Sustainability Index: World and North America
Fast Company: World Changing Ideas (Pandemic Response)
Forbes: World’s Top Female Friendly Companies
Great Place to Work Ireland: Best Workplaces for women
Great Place to Work: Fortune 100 Best Companies to Work For
IDEA Pharma: Pharmaceutical Invention Index, 2021
Newsweek: America’s Most Responsible Companies
1 Revenues excluding REGEN-COV is a measure not calculated in accordance with U.S. Generally Accepted Accounting Principles (“GAAP”). Please see Table 3 of Regeneron’s earnings release announcing its financial and operating results for the quarter and year ended December 31, 2021 for a reconciliation of this measure to the most directly comparable GAAP financial measure.
2 Regeneron records net product sales of EYLEA in the U.S and Bayer records net product sales of EYLEA outside the U.S.
3 Sanofi records global net product sales of Dupixent.
4 Regeneron records net product sales of Libtayo in the U.S. and Sanofi records net product sales of Libtayo outside the U.S.